Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

Authors:
  • KMKurt Miller
    Kurt Miller
  • LBLaurent Boccon-Gibod
    Laurent Boccon-Gibod
  • FSFritz Schröder
    Fritz Schröder
  • NSNeal Shore
    Neal Shore
  • ECE. David Crawford
    E. David Crawford
  • JMJudd Moul
    Judd Moul
  • JJJens-Kristian Jensen
    Jens-Kristian Jensen
  • TOTine Kold Olesen
    Tine Kold Olesen
  • BPBo-Eric Persson
    Bo-Eric Persson

Abstract
No abstract available

This publication has 27 references indexed in Scilit: